, Singapore

Daily Markets Briefing: STI ends flat

Today’s tone likely to turn more downside biased .

OCBC Investment Research said:

The mixed reactions of Wall Street overnight are unlikely to offer any strong cues to the local bourse this morning.

Meanwhile, the STI ended flat yesterday right at the 3070 key resistance; this shows that investors may have turned more cautious about the near term outlook.

And with today’s tone possibly turning more downside biased led by the poor Nikkei start, we could see a pull-back by the index in the direction of the 3030 resistance-turned-support.

Beyond that, the subsequent base lies at the 3000 psychological support. On the upside, 3120 support-turned-resistance remains the next hurdle to overcome.
 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare